Cellular immunotherapy researchers have long been focused on tumor infiltrating lymphocytes (TILs). These naturally occurring anti-cancer cells fight—from inside the tumor—against malignant cells. TIL Cell Therapy is currently being evaluated in clinical trials and encouraging study results have been presented and published.
In this episode, hear from two experts in cancer immunotherapy on the exciting potential of TIL Cell Therapy in melanoma and beyond, where cellular immunotherapy fits into the expanding range of cancer immunotherapies, and what community providers need to know.
Guests:
Sigrun Hallmeyer, MD
Medical Director, Advocate Lutheran General Hospital Cancer Service Line
Medical Director, Advocate Lutheran General Hospital Cancer Survivorship Program
Co-Director, Medical Research, Advocate AuroraHealth
Park Ridge, IL
Mark Faries, MD
Co-director, Melanoma Program and Head of Surgical Oncology
The Angeles Clinic & Research Institute
Los Angeles, CA
Related Content:
